Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > LMNL is being very suttle but they are telling us....
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by sah1on Mar 23, 2020 4:28pm
201 Views
Post# 30839160

RE:RE:RE:RE:LMNL is being very suttle but they are telling us....

RE:RE:RE:RE:LMNL is being very suttle but they are telling us....Gobbs, the company is going to close the R&D facility in Maryland not sell it. This is another clear signal that Lmnl intends to sell the Ryplazim platform probably once regulatory approvals are obtained in USA, Canada and Europe. That is, within the next 2-3 years. In this context, the question is how to maximise the selling price for the Ryplazim platform?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities